助老院于2026年为患有创伤后应激障碍和心理健康疾病的退伍军人启动扩大的MDMA和pislocybin疗法试验。 The VA is launching expanded trials of MDMA and psilocybin therapies for veterans with PTSD and mental health conditions in 2026.

美国退伍军人事务部正在为患有创伤后精神紧张症、抑郁症和焦虑症的退伍军人发起扩大的精神病治疗辅助疗法临床试验——使用MDMA和pislocybin,标志着主流精神保健的一个重要步骤。 The U.S. Department of Veterans Affairs is launching expanded clinical trials of psychedelic-assisted therapies—using MDMA and psilocybin—for veterans with PTSD, depression, and anxiety, marking a major step in mainstream mental health care. 这项研究涉及9个VA医疗中心,定于2026年初开始,这是经过多年的倡导和不断增长的两党支持之后进行的,尽管监管受到挫折,例如林业发展局在2024年底拒绝Lykos制药公司MDMA申请。 The research, involving nine VA medical centers and set to begin in early 2026, follows years of advocacy and growing bipartisan support, despite regulatory setbacks like the FDA’s rejection of a Lykos Pharmaceuticals MDMA application in late 2024. 这些在严格联邦监督下进行的审判包括预备咨询、监测剂量和融合疗法,目的是为不适应传统治疗的退伍军人提供新的选择。 The trials, conducted under strict federal oversight, include preparatory counseling, monitored dosing, and integration therapy, aiming to offer new options for veterans unresponsive to traditional treatments. 虽然进展正在进行中，但由于 FDA 期望的不断变化以及围绕迷幻药的耻辱感，挑战仍然存在。 While progress is underway, challenges remain due to evolving FDA expectations and the stigma surrounding psychedelics.